What Is Wegovy?

Wegovy is the brand name for semaglutide, a medication that activates the glucagon-like peptide-1 (GLP-1) receptor.

GLP-1 is a naturally occurring hormone involved in appetite, satiety, glucose regulation, and digestion. These medications do more than simply make patients "feel less hungry." They alter appetite, satiety, food reward, cravings, and metabolic regulation in ways that make maintaining a lower energy intake substantially easier. However, increased energy expenditure does not appear to be a major mechanism of current GLP-1–based medications.

Wegovy is available in injectable and oral formulations.

How Does Wegovy Work?

Reduces Hunger Signals

Activates GLP-1 receptors in areas of the brain that regulate appetite and satiety, helping reduce hunger and the drive to eat.

Quiets “Food Noise”

Reduces food preoccupation and the rewarding pull of food, making it easier for many people to think about food less and consume fewer calories.

Increases Fullness

Slows gastric emptying, particularly earlier in treatment, and promotes satiety so smaller amounts of food feel more satisfying.

Improves Glucose Regulation

Increases glucose-dependent insulin secretion and reduces glucagon when blood glucose is elevated, helping improve glucose control and insulin sensitivity.

Reduces Stored Body Fat

By substantially reducing caloric intake over time, Wegovy shifts energy balance toward weight loss, with much of the weight lost coming from fat mass, including abdominal and visceral fat.

How Is Wegovy Different From Zepbound?

Wegovy and Zepbound are both used for medical weight management, but they differ in mechanism, formulation, clinical evidence, and FDA-approved indications.

  • Oral or Injectable: Wegovy is available as either an oral semaglutide tablet or a semaglutide injection. Zepbound is currently available only as an injection.
  • Cardiovascular Outcomes: Wegovy is FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.
  • GLP-1 Mechanism: Semaglutide (Wegovy) acts on the GLP-1 receptor. Tirzepatide (Zepbound) is a dual peptide medication and acts on both GIP and GLP-1 receptors.

Is Wegovy the Same as Ozempic?

Wegovy and Ozempic contain the same active medication - semaglutide - but they are FDA-approved for different uses.

Ozempic is primarily used to treat type 2 diabetes, while Wegovy is specifically approved for chronic weight management in appropriate patients with overweight or obesity. Wegovy also has an indication for cardiovascular risk reduction in certain higher-risk patients.

The underlying medication is the same, but the available doses and dosing schedules differ between the two commercial products.

How Much Weight Can You Lose With Wegovy?

Individual response varies, but semaglutide has produced substantial weight loss in clinical trials.

In the landmark STEP 1 trial, adults without diabetes taking once-weekly injectable semaglutide lost approximately 15% of their starting body weight on average over 68 weeks.

Separate clinical trials of oral semaglutide have also demonstrated substantial weight loss. Oral Wegovy (semaglutide 25 mg) resulted in about 13.6% average weight loss at 64 weeks. A useful additional number: 32% of participants with available week-68 data lost at least 20% of their starting body weight.

Some men lose considerably more or less than these averages. Treatment response, tolerability, body composition, metabolic health, and the sustainability of the strategy are all important considerations.

Wegovy Pill vs. Injection

Wegovy is available in oral and injectable formulations, providing different options for semaglutide treatment.

Oral Wegovy

  • Taken once daily
  • Contains semaglutide
  • Avoids injections
  • Requires specific timing around food, beverages, and other medications for reliable absorption
  • Average weight loss of 13% of body weight

Injectable Wegovy

  • Taken once weekly
  • Contains semaglutide
  • Does not require daily medication timing
  • Available in multiple doses to allow gradual titration
  • Average weight loss of 15% of body weight

Wegovy and Cardiovascular Health

One of the most important findings in semaglutide research is evidence that its benefits can extend beyond weight loss.

In the SELECT cardiovascular-outcomes trial, more than 17,600 adults with established cardiovascular disease and overweight or obesity - but without diabetes - received injectable semaglutide or placebo. Major cardiovascular events occurred in 6.5% of participants receiving semaglutide compared with 8.0% receiving placebo, representing a 20% relative reduction in risk.

Based on these data, Wegovy is FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and overweight or obesity.

This indication applies to a specific higher-risk patient population and should not be generalized to everyone taking Wegovy for weight loss.

Wegovy, Visceral Fat, and Men's Metabolic Health

For men, where excess fat is stored matters.

Men tend to accumulate more visceral fat - the deeper abdominal fat surrounding internal organs - which is strongly associated with insulin resistance, cardiovascular disease, abnormal cholesterol, metabolic liver disease, and other cardiometabolic risks.

Weight loss with semaglutide can reduce abdominal fat while improving glucose regulation, insulin sensitivity, blood pressure, triglycerides, and other metabolic markers.

This is one reason we look beyond total body weight and BMI when evaluating treatment response.

Weight Loss Shouldn't Mean Losing Muscle

Significant weight loss can involve loss of both fat and lean tissue. Preserving skeletal muscle is particularly important for men in midlife and beyond.

Our approach emphasizes adequate protein intake, resistance training, appropriate nutrition, and thoughtful medication dosing to support muscle preservation while reducing excess fat.

The goal is better body composition - not simply lower body weight.

Wegovy, Weight Loss, and Testosterone

Excess visceral fat and metabolic dysfunction can contribute to lower testosterone in some men. Conversely, clinically significant testosterone deficiency can contribute to reduced muscle mass and changes in body composition.

Wegovy is not a treatment for low testosterone, and testosterone therapy is not a weight-loss treatment. When symptoms or clinical history warrant it, testosterone evaluation can be considered alongside the broader metabolic assessment.

Learn More About Testosterone Evaluation

What Can I Expect When Taking Wegovy?

The experience varies from person to person.

Many men notice less hunger, earlier fullness, smaller portions, and less interest in food as the dose is gradually increased. Men often report less "food noise."

Nausea, diarrhea or constipation, vomiting, abdominal discomfort, or reflux can occur. However, many of these side effects can be mitigated or avoided through "low and slow" dosing i.e., gradual titration based on response and tolerability.

Wegovy Side Effects and Safety

The most common side effects of Wegovy are gastrointestinal and may include:

  • Nausea
  • Diarrhea
  • Constipation
  • Vomiting
  • Abdominal discomfort
  • Indigestion or acid reflux (GERD)

More significant adverse effects can occur and should be reviewed before treatment.

Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in animal studies and should not be used in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). GLP-1s have also been associated with increased risks of pancreatitis, gallbladder problems, kidney injury from dehydration, gastrointestinal effects including gastroparesis

Who Is a Candidate for Wegovy?

Wegovy is approved for long-term weight management in adults with obesity, or adults with overweight plus at least one weight-related health condition, when appropriate.

Men often seek treatment because of increasing abdominal or visceral fat, worsening metabolic markers, prediabetes, sleep apnea, repeated weight regain, or weight that has become increasingly difficult to manage.

Eligibility for a medication and the decision to use it are not necessarily the same thing.

We also consider:

  • Metabolic risk
  • Cardiovascular disease or disease risk
  • Body composition and visceral fat
  • Prediabetes or insulin resistance
  • Sleep apnea
  • Weight history and previous treatment
  • Medical history and contraindications
  • Treatment goals and patient preference

For some men, another medication - or a strategy that does not involve medication - may be more appropriate.

How Is Wegovy Dosed and Monitored?

Wegovy is typically started at a low dose and increased gradually as the body adjusts. Commercial Wegovy pens use fixed-dose increments, but when clinically appropriate, other prescribed vial formulations may allow smaller, intermediate dose adjustments and a more gradual titration based on individual response and tolerability.

At Performance Men's Health, the goal is not simply to increase the dose as quickly as possible. We monitor appetite, weight trajectory, side effects, metabolic markers, and changes in body composition. We do not routinely aim for the maximum dose. Many patients can achieve meaningful weight loss at lower doses.

Protein intake, resistance training, sleep, and other factors that support muscle preservation and long-term metabolic health are addressed throughout treatment.

START LOW → TITRATE INDIVIDUALLY → MONITOR RESPONSE → PRESERVE MUSCLE → PLAN FOR MAINTENANCE

What Happens If You Stop Wegovy?

Weight regain after stopping semaglutide is common because the biological signals involved in hunger and weight regulation can return when medication is discontinued.

That does not mean every patient must remain on the same medication or dose indefinitely. Long-term strategies may include continued therapy, individualized dosing, transitioning treatment, or carefully monitored discontinuation.

Planning for weight maintenance should begin before goal weight is reached.

Wegovy vs. Zepbound: A Closer Comparison

ZEPBOUND® WEGOVY®
Active medication Tirzepatide Semaglutide
Mechanism GIP + GLP-1 GLP-1
Formulation Once-weekly injection Injection or oral tablet
Head-to-head average weight loss* 20.20% 13.70%
Additional FDA indication highlighted here Moderate-to-severe OSA in adults with obesity Cardiovascular risk reduction in certain adults with established CVD and overweight or obesity

*SURMOUNT-5 was a head to head trial that compared maximum tolerated doses of injectable semaglutide and tirzepatide over 72 weeks in adults with obesity without diabetes. In this trial, patients lost an average of 13.7% of their body weight.

Learn More About Zepbound

Wegovy at Performance Men's Health

Wegovy can be a highly effective weight loss treatment for appropriate men, but medication is only one component of weight management.

Our approach considers visceral fat, muscle mass, metabolic health, nutrition, exercise, medication response, testosterone screening, and long-term maintenance strategies.

Frequently Asked Questions

Frequently Asked Questions About Wegovy

Is Wegovy the same as semaglutide?

Is Wegovy the same as Ozempic?

Does Wegovy come in pill form?

Does oral Wegovy work as well as the injection?

What is Wegovy HD?

How quickly does Wegovy start working?

How much weight can I expect to lose with Wegovy?

Can Wegovy reduce the risk of heart attack or stroke?

Will I lose muscle on Wegovy?

Can losing weight with Wegovy improve testosterone?

Do I have to take Wegovy forever?

Is Wegovy better than Zepbound?

Can Wegovy help with prediabetes or insulin resistance?

Your current health isn't your ceiling – it's your starting point.

Schedule a consultation with the Performance Men's Health team.